Direct immunomodulatory influence of IFN-β on human astrocytoma cells

References

• Pivneva TA. Microglia in normal condition and pathology. Fiziol Zh 2008;54:81–89
   Google Scholar
• Mirshafiey A. Venom therapy in multiple sclerosis. Neuropharmacology 2007;53:353–361
   PubMedGoogle Scholar
• Brück W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 2005;252:v3–v9
   Web of Science ®Google Scholar
• Reske D, Thomas AV, Petereit HF, et al. Impact of immunomodulatory treatment on leukocyte cytokine production in multiple sclerosis patients and healthy donors. Neuroimmunomodulation 2009;16:385–391
   PubMedGoogle Scholar
• Kasper LH, Reder AT. Immunomodulatory activity of interferon-beta. Ann Clin Transl Neurol 2014;1:622–631
   PubMed Web of Science ®Google Scholar
• Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs 2011;1:491–502
   Google Scholar
• Brosnan CF, Raine CS. The astrocyte in multiple sclerosis revisited. Glia 2013;61:453–465
   PubMed Web of Science ®Google Scholar
• Nair A, Frederick TJ, Miller SD. Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 2008;65:2702–2720
   PubMed Web of Science ®Google Scholar
• Saha RN, Pahan K. Regulation of inducible nitric oxide synthase gene in glial cells. Antioxid Redox Signal 2006;8:929–947
   PubMed Web of Science ®Google Scholar
• Broholm H, Andersen B, Wanscher B, et al. Nitric oxide synthase expression and enzymatic activity in multiple sclerosis. Acta Neurol Scand 2004;109:261–269
   PubMed Web of Science ®Google Scholar
• Petković F, Blaževski J, Momčilović M, et al. Nitric oxide inhibits CXCL12 expression in neuroinflammation. Immunol Cell Biol 2013;91:427–434
   PubMedGoogle Scholar
• Calabrese V, Scapagnini G, Ravagna A, et al. Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res 2003;28:1321–1328
   PubMedGoogle Scholar
• Li YH, Liu CY, Zhang PJ, et al. Effect of Fasudil on miroglia and astrocytes in experimental autoimmune encephalomyelitis mice. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2012;28:1242–1245 [in Chinese]
   PubMedGoogle Scholar
• Mirshafiey A, Mohsenzadegan M. Antioxidant therapy in multiple sclerosis. Immunopharmacol Immunotoxicol 2009;31:13–29
   PubMed Web of Science ®Google Scholar
• Agrawal SM, Yong VW. Immunopathogenesis of multiple sclerosis. Int Rev Neurobiol 2007;79:99–126
   PubMed Web of Science ®Google Scholar
• Könnecke H, Bechmann I. The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas. Clin Dev Immunol 2013;2013:914104
   PubMedGoogle Scholar
• Karabudak R, Kurne A, Guc D, et al. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results. J Neurol 2004;251:279–283
   PubMedGoogle Scholar
• Miljković D, Timotijević G, Mostarica Stojković M. Astrocytes in the tempest of multiple sclerosis. FEBS Lett 2011;585:3781–3788
   PubMedGoogle Scholar
• Liu BS, Janssen HL, Boonstra A. Type I and III interferons enhance IL-10R expression on human monocytes and macrophages, resulting in IL-10-mediated suppression of TLR-induced IL-12. Eur J Immunol 2012;42:2431–2440
   PubMedGoogle Scholar
• Ersoy E, Kuş CN, Sener U, et al. The effects of interferon-beta on interleukin-10 in multiple sclerosis patients. Eur J Neurol 2005;12:208–211
   PubMedGoogle Scholar
• Imitola J, Chitnis T, Khoury SJ. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther 2005;106:163–177
   PubMed Web of Science ®Google Scholar
• Byrnes AA, McArthur JC, Karp CL. Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol 2002;51:165–174
   PubMed Web of Science ®Google Scholar
• Waubant E, Gee L, Bacchetti P, et al. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing-remitting MS. J Neuroimmunol 2001;112:139–145
   PubMedGoogle Scholar
• Rentzos M, Nikolaou C, Rombos A, et al. Effect of treatment with methylprednisolone on the serum levels of IL-12, IL-10 and CCL2 chemokine in patients with multiple sclerosis in relapse. Clin Neurol Neurosurg 2008;110:992–996
   PubMed Web of Science ®Google Scholar
• González H, Elgueta D, Montoya A, Pacheco R. Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J Neuroimmunol 2014;274:1–13
   PubMed Web of Science ®Google Scholar
• Gresa-Arribas N, Viéitez C, Dentesano G, et al. Modelling neuroinflammation in vitro: a tool to test the potential neuroprotective effect of anti-inflammatory agents. PLoS One 2012;7:e45227
   PubMed Web of Science ®Google Scholar
• Graber JJ, Ford D, Zhan M, et al. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J Neuroimmunol 2007;185:168–174
   PubMed Web of Science ®Google Scholar
• Zhang L, Yuan S, Cheng G, Guo B. Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. PLoS One 2011;6:e28432
   Web of Science ®Google Scholar
• Ho HJ, Huang DY, Ho FM, et al. Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase expression by endoplasmic reticulum stress. Cell Signal 2012;24:2166–2178
   PubMedGoogle Scholar
• Louin G, Marchand-Verrecchia C, Palmier B, et al. Selective inhibition of inducible nitric oxide synthase reduces neurological deficit but not cerebral edema following traumatic brain injury. Neuropharmacology 2006;50:182–190
   PubMedGoogle Scholar
• Jafarian-Tehrani M, Louin G, Royo NC, et al. 1400W, a potent selective inducible NOS inhibitor, improves histopathological outcome following traumatic brain injury in rats. Nitric Oxide 2005;12:61–69
   PubMed Web of Science ®Google Scholar
• Yoo BK, Choi JW, Shin CY, et al. Activation of p38 MAPK induced peroxynitrite generation in LPS plus IFN-gamma-stimulated rat primary astrocytes via activation of iNOS and NADPH oxidase. Neurochem Int 2008;52:1188–1197
   PubMedGoogle Scholar
• Guthikonda P, Baker J, Mattson DH. Interferon-beta-1-b (IFN-B) decreases induced nitric oxide (NO) production by a human astrocytoma cell line. J Neuroimmunol 1998;82:133–139
   PubMedGoogle Scholar
• Yushchenko M, Mäder M, Elitok E, et al. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. J Neurol 2003;250:1224–1228
   PubMedGoogle Scholar
• Sellebjerg F, Sorensen TL. Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull 2003;61:347–355
   PubMed Web of Science ®Google Scholar
• Leppert D, Waubant E, Burk MR, et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846–852
   PubMed Web of Science ®Google Scholar
• Liuzzi GM, Latronico T, Fasano A, et al. Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult Scler 2004;10:290–297
   PubMedGoogle Scholar